Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2021 | Treating CNS metastases in HER2+ breast cancer

Thomas Bachelot • 21 Apr 2021
ESMO Breast 2021
Breast Cancer Antibodies Capecitabine Trastuzumab Tucatinib

Thomas Bachelot, MD, PhD, Centre Léon Bérard, Lyon, France, talks on whether treatment of central nervous system (CNS) metastases in HER2+ breast cancer requires a different systemic approach. Dr Bachelot reports that most treatments used for metastatic breast cancer are equally active on brain metastases and systemic disease. Dr Bachelot also comments on the role of novel drug combinations for the treatment of patients with brain cancer and active brain metastases, highlighting the benefits of tucatinib, trastuzumab and capecitabine in combination. This interview took place at the virtual European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021.

More from Thomas Bachelot

Sequencing therapies in HER2+ breast cancer
2:22
Sequencing therapies in HER2+ breast cancer
Thomas Bachelot • 21 Apr 2021
SAFIR02-IMMUNO: PDL1 copy number changes predicts checkpoint blockade inhibitor efficacy in mBC
6:46
SAFIR02-IMMUNO: PDL1 copy number changes predicts checkpoint blockade inhibitor efficacy in mBC
Thomas Bachelot • 22 May 2020

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals